Detail akcie Biogen Idec online

Business Summary: Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Biogen Inc revenues increased 3% to $5.21B. Net income decreased 52% to $417M. Revenues reflect United States segment increase from $2.17B to $4.81B, United states-Revenues from anti-CD20 therapeutic segment increase of 10% to $932.6M. Net income was offset by Biopharmaceutical segment income decrease of 53% to $548.3M.